S. 2973 118th Congress
Modernizing and Ensuring PBM Accountability Act
Latest action, Dec 7, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 266.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
Sponsor
Sponsored by Ron Wyden (Democrat). No cosponsors.
Referred to: Senate: Finance Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
6 reports
AMERICAN PHARMACY COOPERATIVE, INC.
ARENTFOX SCHIFF LLP
6 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
AKIN GUMP STRAUSS HAUER & FELD
6 reports
CAMBIA HEALTH SOLUTIONS (FORMERLY KNOWN AS THE REGENCE GROUP)
RED+BLUE STRATEGIES
6 reports
6 reports
6 reports
6 reports
INDEPENDENT PHARMACY COOPERATIVE
FORBES-TATE
6 reports
6 reports
6 reports
LUNDBECK PHARMACEUTICALS LLC
CAPITOL COUNSEL LLC
6 reports
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION (NCPA)
CAPITOL COUNSEL LLC
6 reports
6 reports
6 reports
All 25 of 95 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| 340B HEALTH | 6 | $1.9M | Q4 2023 | Q3 2024 | yes | |
| AMERICAN PHARMACY COOPERATIVE, INC. | ARENTFOX SCHIFF LLP | 6 | $180K | Q4 2023 | Q3 2024 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | AKIN GUMP STRAUSS HAUER & FELD | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| CAMBIA HEALTH SOLUTIONS (FORMERLY KNOWN AS THE REGENCE GROUP) | RED+BLUE STRATEGIES | 6 | $480K | Q4 2023 | Q3 2024 | yes |
| CYSTIC FIBROSIS FOUNDATION | 6 | $1.1M | Q4 2023 | Q3 2024 | yes | |
| FOOD MARKETPLACE INC | 6 | $2.0M | Q4 2023 | Q3 2024 | yes | |
| INDEPENDENT PHARMACY COOPERATIVE | 6 | $300K | Q4 2023 | Q3 2024 | yes | |
| INDEPENDENT PHARMACY COOPERATIVE | FORBES-TATE | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| INTRA-CELLULAR THERAPIES, INC. | 6 | $260K | Q4 2023 | Q3 2024 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 6 | $3.7M | Q4 2023 | Q3 2024 | yes | |
| LUNDBECK PHARMACEUTICALS LLC | CAPITOL COUNSEL LLC | 6 | $240K | Q4 2023 | Q3 2024 | yes |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 6 | $2.1M | Q4 2023 | Q3 2024 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION (NCPA) | CAPITOL COUNSEL LLC | 6 | $300K | Q4 2023 | Q3 2024 | yes |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 6 | $393K | Q4 2023 | Q3 2024 | yes | |
| NOVARTIS | 6 | $8.3M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | RED+BLUE STRATEGIES | 6 | $420K | Q4 2023 | Q3 2024 | yes |
| ST LUKE'S HEALTH PLAN, INC. | VERITAS ADVISORS, LLP | 6 | $60K | Q4 2023 | Q3 2024 | yes |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 6 | $11.8M | Q4 2023 | Q3 2024 | yes | |
| AMERICAN PHARMACIES, INC. | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) | 5 | $300K | Q4 2023 | Q3 2024 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 5 | $8.9M | Q4 2023 | Q3 2024 | yes | |
| BLUE CROSS BLUE SHIELD ASSOCIATION | AVENUE SOLUTIONS | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| CENCORA FKA AMERISOURCEBERGEN CORPORATION | HORIZON GOVERNMENT AFFAIRS | 5 | $250K | Q4 2023 | Q3 2024 | yes |
| CVS HEALTH (AND SUBSIDIARIES) | 5 | $11.0M | Q4 2023 | Q3 2024 | yes | |
| EISAI INC. | 5 | $3.1M | Q4 2023 | Q3 2024 | yes |